Adjuvant olaparib for patients with germline BRCA-mutated, high-risk, HER2-negative early breast cancer: real-world data from a French early access program.
Overview & Synopsis
Open access biomedical research article published in ESMO Real World Data Digit Oncol.
Indexed from repository: PubMed Central
(
pmc.ncbi.nlm.nih.gov)
Keyboard Shortcuts:
← / → for pages • + / - for zoom • 0 to fit width
Powered by Mozilla PDF.js v3.11
Document Information
| Document Title | Adjuvant olaparib for patients with germline BRCA-mutated, high-risk, HER2-negative early breast cancer: real-world data from a French early access program. |
|---|---|
| Author / Organization | Frenel JS, Gonçalves A, Quintin J, Johnson A, Alexandru C, Olympios N, Rigal O, Bonnard C, Lahouegue A, Lazreg F, Suau D, Debbache A, de Nonneville A |
| Subject & Discipline | ESMO Real World Data Digit Oncol |
| Categories | Medicine & Health |
| Publication Year | 2026 |
| License / Rights | Open Access / Creative Commons |
| Resource Verification | Listed PDF (Verification Pending) |
| Original Host Website |
PubMed Central
(pmc.ncbi.nlm.nih.gov)
|
| File Format | application/pdf (Portable Document Format) |
| Language | EN |
| Catalog ID | DOC-8223 |
| Original Source Link | Visit Source Page on pmc.ncbi.nlm.nih.gov » |